Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study

被引:200
|
作者
Khunti, K. [1 ]
Alsifri, S. [2 ]
Aronson, R. [3 ]
Berkovic, M. Cigrovski [4 ]
Enters-Weijnen, C. [5 ]
Forsen, T. [6 ]
Galstyan, G. [7 ]
Geelhoed-Duijvestijn, P. [8 ]
Goldfracht, M. [9 ,10 ]
Gydesen, H. [11 ]
Kapur, R. [11 ]
Lalic, N. [12 ]
Ludvik, B. [13 ,14 ]
Moberg, E. [15 ]
Pedersen-Bjergaard, U. [16 ]
Ramachandran, A. [17 ,18 ]
机构
[1] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[2] Al Hada Mil Hosp, At Taif, Saudi Arabia
[3] LMC Diabet & Endocrinol, Toronto, ON, Canada
[4] Univ Hosp Sestre Milosrdnice, Zagreb, Croatia
[5] UMC Utrecht, Julius Clin Julius Ctr, Zeist, Netherlands
[6] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland
[7] Endocrinol Res Ctr, Moscow, Russia
[8] Med Ctr Haaglanden, The Hague, Netherlands
[9] Clalit Hlth Serv, Tel Aviv, Israel
[10] Technion, Haifa, Israel
[11] Novo Nordisk AS, Soborg, Denmark
[12] Univ Belgrade, Clin Ctr Serbia, Clin Endocrinol Diabet & Metab Dis, Fac Med, Belgrade, Serbia
[13] Rudolfstiftung Hosp, Vienna, Austria
[14] Med Univ Vienna, Vienna, Austria
[15] Karolinska Inst, Stockholm, Sweden
[16] Nordsjaellands Hosp Hillerod, Hillerod, Denmark
[17] India Diabet Res Fdn, Madras, Tamil Nadu, India
[18] Dr A Ramachandrans Diabet Hosp, Chennai, Tamil Nadu, India
关键词
diabetes; global; HAT study; hypoglycaemia; insulin; observational; BASE-LINE CHARACTERISTICS; DOSING IRREGULARITIES; AUTONOMIC FAILURE; PATIENT; POPULATION; MANAGEMENT; FREQUENCY; COHORT; IMPACT;
D O I
10.1111/dom.12689
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To determine the global extent of hypoglycaemia experienced by patients with diabetes using insulin, as there is a lack of data on the prevalence of hypoglycaemia in developed and developing countries. Methods: This non-interventional, multicentre, 6-month retrospective and 4-week prospective study using self-assessment questionnaire and patient diaries included 27 585 patients, aged >= 18 years, with type 1 diabetes (T1D; n = 8022) or type 2 diabetes (T2D; n = 19 563) treated with insulin for > 12 months, at 2004 sites in 24 countries worldwide. The primary endpoint was the proportion of patients experiencing at least one hypoglycaemic event during the observational period. Results: During the prospective period, 83.0% of patients with T1D and 46.5% of patients with T2D reported hypoglycaemia. Rates of any, nocturnal and severe hypoglycaemia were 73.3 [95% confidence interval (CI) 72.6-74.0], 11.3 (95% CI 11.0-11.6) and 4.9 (95% CI 4.7-5.1) events/patient-year for T1D and 19.3 (95% CI 19.1-19.6), 3.7 (95% CI 3.6-3.8) and 2.5 events/patient-year (95% CI 2.4-2.5) for T2D, respectively. The highest rates of any hypoglycaemia were observed in Latin America for T1D and Russia for T2D. Glycated haemoglobin level was not a significant predictor of hypoglycaemia. Conclusions: We report hypoglycaemia rates in a global population, including those in countries without previous data. Overall hypoglycaemia rates were high, with large variations between geographical regions. Further investigation into these differences may help to optimize therapy and reduce the risk of hypoglycaemia.
引用
收藏
页码:907 / 915
页数:9
相关论文
共 50 条
  • [41] Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study
    Balkau, Beverley
    Calvi-Gries, Francoise
    Freemantle, Nick
    Vincent, Maya
    Pilorget, Valerie
    Home, Philip D.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 108 (03) : 432 - 440
  • [42] Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries
    Frechtel, Gustavo
    Sauque-Reyna, Leobardo
    Choza-Romero, Ricardo
    Anguiano, Luis
    Melas-Melt, Lydie
    Sanudo-Maury, Maria Elena
    DIABETES OBESITY & METABOLISM, 2023, 25 (09) : 2526 - 2534
  • [43] High prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with insulin-treated type 2 diabetes: The Dutch Diabetes Pearl Cohort
    van Meijel, Lian A.
    de Vegt, Femmie
    Abbink, Evertine J.
    Rutters, Femke
    Schram, Miranda T.
    van der Klauw, Melanie M.
    Wolffenbuttel, Bruce H. R.
    Siegelaar, Sarah
    DeVries, J. Hans
    Sijbrands, Eric J. G.
    Ozcan, Behiye
    de Valk, Harold W.
    Silvius, Bianca
    Schaper, Nicolaas
    Stehouwer, Coen D. A.
    Elders, Petra J. M.
    Tack, Cornelis J.
    de Galan, Bastiaan E.
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
  • [44] Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin
    Chan, John Y. C.
    Leyk, Malgorzata
    Frier, Brian M.
    Tan, Meng H.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2009, 25 (03) : 224 - 231
  • [45] Cost-Utility of Real-Time Continuous Glucose Monitoring versus Self-Monitoring of Blood Glucose in People with Insulin-Treated Type 2 Diabetes in Spain
    Merino-Torres, Juan Francisco
    Ilham, Sabrina
    Alshannaq, Hamza
    Pollock, Richard F.
    Ahmed, Waqas
    Norman, Gregory
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2024, 16 : 785 - 797
  • [46] Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus
    Philis-Tsimikas, A.
    Astamirova, K.
    Gupta, Y.
    Haggag, A.
    Roula, D.
    Bak, B. A.
    Fita, E. G.
    Nielsen, A. M.
    Demir, T.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 147 : 157 - 165
  • [47] Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
    Heller, Simon R.
    DeVries, J. Hans
    Wysham, Carol
    Hansen, Charlotte T.
    Hansen, Melissa V.
    Frier, Brian M.
    DIABETES OBESITY & METABOLISM, 2019, 21 (07) : 1634 - 1641
  • [48] Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43)
    Satoh, Jo
    Andersen, Marc
    Hansen, Brian Bekker
    Thorsted, Brian Larsen
    Tutkunkardas, Deniz
    Zacho, Mette
    Maegawa, Hiroshi
    PLOS ONE, 2018, 13 (09):
  • [49] Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials
    DeVries, J. Hans
    Bailey, Timothy S.
    Bhargava, Anuj
    Gerety, Gregg
    Gumprecht, Janusz
    Heller, Simon
    Lane, Wendy
    Wysham, Carol H.
    Zinman, Bernard
    Bak, Britta A.
    Hachmann-Nielsen, Elise
    Philis-Tsimikas, Athena
    DIABETES OBESITY & METABOLISM, 2019, 21 (03) : 622 - 630
  • [50] Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
    Cariou, B.
    Leiter, L. A.
    Mueller-Wieland, D.
    Bigot, G.
    Colhoun, H. M.
    Del Prato, S.
    Henry, R. R.
    Tinahones, F. J.
    Letierce, A.
    Aurand, L.
    Maroni, J.
    Ray, K. K.
    Bujas-Bobanovic, M.
    DIABETES & METABOLISM, 2017, 43 (05) : 453 - 459